Trial · NCT01191541
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR Group | relapse | 1 | participants | |
| the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR+Ara-C Group | relapse | 0 | participants | |
| the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR Group | died | 0 | participants | |
| the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR+Ara-C Group | died | 0 | participants | |
| the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR+Ara-c(Ara-C Group) | relapse | 0 | participants | |
| the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR(No Ara-C Group) | relapse | 1 | participants | |
| the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR+Ara-c(Ara-C Group) | die | 0 | participants | |
| the Event-free Survival (EFS） of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial | DNR(No Ara-C Group) | die | 0 | participants | |
| Number of Participants With Side Effects | DNR+Ara-c (Ara-C Group) | sepsis | 5 | Participants | |
| Number of Participants With Side Effects | DNR (No Ara-c Group) | sepsis | 1 | Participants | |
| Number of Participants With Side Effects | DNR+Ara-c (Ara-C Group) | platelet transfusion | 26 | Participants | |
| Number of Participants With Side Effects | DNR (No Ara-c Group) | platelet transfusion | 0 | Participants | |
| Number of Participants With Side Effects | DNR+Ara-c (Ara-C Group) | red blood cell transfusion | 7 | Participants | |
| Number of Participants With Side Effects | DNR (No Ara-c Group) | red blood cell transfusion | 7 | Participants | |
| Number of Participants With Side Effects | DNR+Ara-c (Ara-C Group) | relapse | 0 | Participants | |
| Number of Participants With Side Effects | DNR (No Ara-c Group) | relapse | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01191541/results